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Adherence-enhancing interventions have been assessed in the literature, however hetero-
geneity and conflicting findings have prohibited a consensus on the most effective approach
to maintain adherence over time. With the ageing population and growth of chronic condi-
tions, evaluation of sustainable strategies to improve and maintain medication adherence
long term is paramount. We aimed to determine the comparative effectiveness of interven-
tions for improving medication adherence over time among adults with any clinical
condition.
Materials and methods
Meta-analyses evaluating interventions to improve medication adherence were searched in
PubMed in January 2019 and reviewed for primary studies. Experimental studies with a
comparison group assessing an intervention to enhance medication adherence in adult
patients with reported adherence outcomes were included. Two authors extracted data for
study characteristics, interventions and adherence outcomes. Interventions were catego-
rized into four groups or combinations: educational, attitudinal, technical and rewards. Four
network meta-analyses were performed to compare interventions based on patient follow-
up time. Medication adherence effect sizes were reported as odds ratios (OR) with a 95%
credibility interval (CrI) and surface under the cumulative ranking curve (SUCRA) to allow
ranking probabilities. Risk of bias was assessed as per Cochrane guidelines.
Results
Data was obtained from 69 meta-analyses with 468 primary studies being included in quali-
tative synthesis. The four networks compromised of 249 studies in total (0–3 month follow-
up: 99 studies, 4–6 months: 104, 7–9 months: 18,�10 months: 94). Interventions showing
success in follow-ups of less than 10 months varied across time. Significant effects
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compared to standard of care (SOC) were found in technical (4–6 months: OR 0.34, 95%
CrI 0.25–0.45) and attitudinal interventions (7–9 months: 0.37, 0.17–0.84). Multicomponent
interventions demonstrated effectiveness compared to standard of care with an additive
effect displayed, particularly in longer follow-ups (educational + attitudinal + technical inter-
ventions�10 months: OR 0.49, 95% CrI 0.27–0.88).
Discussion
All interventions reviewed improved medication adherence compared to standard of care.
Multicomponent interventions displayed the most promising results in maintenance of long-
term medication adherence. Technical and reward components enhanced adherence on a
short-term basis, while educational and attitudinal interventions evolved over time to be
more effective in follow-ups greater than 7 months. Sustainability of adherence to medica-
tions over time is dependent upon multicomponent interventions including educational, atti-
tudinal and technical aspects to modify and enhance patient medication-taking behavior.
Future research should focus on the most cost-effective approaches able to be integrated
into routine practice.
Introduction
A significant proportion of health care system funding is spent on medications, with 10% of
U.S. national health expenditure attributed to prescription medications in 2016 [1]. As only
50% of patients reportedly take their medications as prescribed, medication non-adherence is
a major challenge for the health care system [2]. Suboptimal adherence to prescribed medica-
tions not only increases health care costs but also increases the possibility of poor health out-
comes, adverse events and hospitalizations [3, 4]. It is estimated that failure to adhere to
medications results in $290 billion per year in unnecessary expenditure in the U.S. [5].
Adherence is not simply a matter of patient choice or will [6–10], but is affected by the
interplay of multiple determinants of adherence that the World Health Organization (WHO)
has classified into five different dimensions–condition-related factors, therapy-related factors,
patient-related factors, socio-economic factors and healthcare team and system-related factors.
While patient population characteristics may have an effect on adherence, determinants and
barriers for non-adherence are often comparable across different medications and clinical con-
ditions. [11–13].
Medication adherence can be conceptualized as having three major components: (1) initia-
tion–when the patient takes the first dose of a prescribed medication; (2) implementation–the
extent to which a patient’s actual dosing corresponds to the prescribed dosing regimen from
initiation until the last dose is taken, and (3) persistence–the time from initiation to discontin-
uation [14]. Non-adherence can occur in any of these phases, and may change over time in
patients. There is substantive evidence of a declining trend in adherence over time [15–18],
and many determinants of non-adherence are found to be affected by time [6]. Time-related
factors are particularly important for people with chronic diseases, where lifetime adherence
to therapy may be required.
Numerous multifaceted adherence-enhancing interventions, ranging from simple educa-
tional material to multicomponent approaches integrating advanced behavioral and educa-
tional techniques, have been proposed and tested in a wide variety of settings, populations
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and clinical conditions, using a wide range of measures of adherence [11, 19, 20]. Recent
meta-analyses have not reached a decisive conclusion, with some suggesting cognitive-educa-
tional interventions are effective [21] and others promoting habit-based strategies [19]. A
Cochrane systematic review also concluded interventions’ effects were inconsistent across
studies, however, they found the most effective interventions to be complex with frequent
patient interaction [11]. Unfortunately there is additionally a lack of direct, head-to-head evi-
dence of intervention strategies and combined with the complexity of the literature, makes it a
challenge to select evidence-based interventions for implementation in routine clinical
practice.
Network meta-analysis is a technique recommended by the International Society for Phar-
macoeconomics and Outcome Research to compare efficacy among different interventions
[22]. Compared with pairwise meta-analyses, it provides robust comparative evidence, allow-
ing for estimates of relative treatment effects on both direct and indirect evidence [23]. This
approach to evaluate all treatment options to each other simultaneously allows more optimal
guidance on comparing interventions to other interventions rather than the common compar-
ator of standard of care alone.
The aim of this systematic review and network meta-analysis was to analyze the compara-
tive effectiveness of interventions for improving medication adherence over time among adults
with any clinical condition.
Materials and methods
The PRISMA extension to network meta-analysis and Cochrane Collaboration recommenda-
tions to design and report were used for this systematic review and network meta-analysis
[24–26]. The review is registered on PROSPERO at CRD42018054598.
Data sources
A systematic search of the medical literature was conducted for relevant meta-analyses com-
paring patient-targeted interventions to improve medication adherence in adult populations
reporting adherence outcomes. The search was conducted on PubMed in January 2019 with-
out any restriction based on publication date or language. The complete search strategy is
available in S1 Table. Two investigators (EW, ATR) independently reviewed all abstracts and
full-text articles and discrepancies were solved by a third reviewer. The primary studies
included in the meta-analyses were then fully reviewed.
Study selection
Primary experimental design studies with a comparison group that assessed an intervention
with the objective of improving medication adherence in adult patients and which reported
implementation adherence as an outcome using any measure (e.g. self-report, pill count, elec-
tronic monitoring) were included. Other active interventions or standard of care were consid-
ered as comparators. Unpublished studies, articles written in non-Roman characters, with
pediatric populations (<18 years), assessing interventions targeted at healthcare professionals
or studies using other types of treatment (over-the-counter medications, depot medications,
vaccines) were excluded. Studies were not restricted by country, clinical condition or trial fol-
low-up. Eligible primary studies with categorical medication adherence outcomes (i.e. adher-
ent vs non-adherent) were included in the network meta-analyses while those with continuous
outcomes were only included in the qualitative analysis.
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Data extraction and quality assessment
The following data from primary articles was extracted by two investigators (EW, ATR) using
a standard data sheet piloted with 28 studies: study baseline characteristics (authors, year, title,
sample size, clinical condition, demographics, duration of study, evaluated interventions),
study design, measure of adherence used, variable type (continuous versus categorical) and
corresponding adherence rates before and after the intervention.
To standardize the results obtained from different measures of adherence, an overall com-
posite adherence outcome was used for categorical variables that represented the rate of adher-
ent patients obtained from any of the measures in each study. The overall composite score was
validated by Tonin et al, 2018 [27]. If a study included more than one measure, a mean rate
from the different measures of adherence was calculated.
According to the patient follow-up period of each included study, results were grouped
based on patient follow-up and results of adherence reported into standardized periods of
time: 0–3 months, 4–6 months, 7–9 months, and� 10 months.
To improve interpretability, interventions were grouped into four categories: attitudinal
components aiming to modify beliefs, reward components creating incentives, educational
components to inform on the medication, disease state, or importance of adherence, and tech-
nical components intended to simplify the medication taking process. The development and
categorization process was discussed in Tonin et al, 2018 [27], and full category definitions can
be found in S2 Table. Multicomponent interventions included more than one single category
(e.g. rewards + technical). Standard of care was considered as the usual care defined in the pri-
mary study.
Two reviewers (EW, ATR) assessed all articles using the Cochrane Risk of Bias tool [28].
Given the complexity of interventions and to avoid a floor effect, adjusted criteria for judge-
ment of risk of bias were used. The adjusted criteria allowed for low risk of bias indicated if
outcomes were not blinded but were measured with validated instruments (i.e. previously vali-
dated medication adherence questionnaires).
Data analysis
Network meta-analysis was performed using Bayesian framework to analyze the comparative
adherence of all the interventions for the overall composite measure of categorical measures in
each time period. Interventions were modelled as they were described in the original studies,
that is, as different combinations of components. Only implementation adherence outcomes
could be used for comparison purposes. For all comparisons, a common heterogeneity param-
eter was assumed, and a conservative analysis of non-informative priors was chosen [29, 30].
Effect sizes measures were expressed as odds ratio (OR) with a 95% credibility interval (CrI).
Heterogeneity between trial comparisons was estimated by using the I2 statistic. Both random
and fixed effect models were tested. The goodness of fit of the model was assessed using resid-
ual deviances (DIC). Models with lowest DIC were used. Convergence was attained based on
visual inspection of Brooks-Gelman-Rubin plots and potential scale reduction factor—PSRF
(1<PSRF�1.05) [30, 31]. To increase the estimate precision of the relative effect sizes of com-
parisons and to account properly for correlations between multi-arm trials, rank probabilities
involving all the interventions were built for each outcome. The surface under the cumulative
ranking curve (SUCRA) analysis was performed to present results of ranking order. SUCRA
values can range from 0% (i.e. the intervention always ranks last) to 100% (i.e. the intervention
always ranks first) [32]. Node-splitting analyses were used to assess inconsistency in the net-
works (p-values<0.05 reveal significant inconsistencies in the network) [33]. All analyses were
performed using software Addis version 1.17.6 [34]. Other sensitivity analyses with the
Interventions to improve medication adherence
PLOS ONE | https://doi.org/10.1371/journal.pone.0213432 March 12, 2019 4 / 16
hypothetical removal or inclusion of the studies were conducted based on article’s year of pub-
lication (before or after 2007) and sample size (total number of included patients over 30).
Results
Database searching identified 1081 records. Sixty-nine meta-analyses were included for pri-
mary study extraction. From these, 1234 primary studies were identified and 468 studies were
included for qualitative synthesis (see Fig 1) (S1 Appendix). The most common single
Fig 1. Flowchart of the systematic review process and included studies.
https://doi.org/10.1371/journal.pone.0213432.g001
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interventions were educational (n = 172 studies), followed by technical (n = 118), attitudinal
(n = 57) and rewards (n = 2). Combinations of two or more categories of interventions were
found in 191 trials (41.0%) with most of them reporting educational + technical (n = 94), edu-
cational + attitudinal (n = 62) and educational + attitudinal + technical (n = 25). Standard
of care was the common comparator in 88.0% of studies. The earliest studies were published
in 1971 and the most recent in 2017 (median = 2008; IQR 2002–2012). Twelve clinical condi-
tions were included with the most common being cardiovascular (n = 206 studies) and HIV
(n = 96).
Risk of bias assessment revealed most studies having an unclear risk of bias. The domains
with higher risk of bias were attrition bias (around 25% of studies) and performance bias (30%
of studies) as studies lacked complete outcome data or were unable to blind participants due to
the nature of the interventions. More than 90% of studies were free of selective reporting.
Fewer than 10% of trials were sponsored by industries or presented conflict of interest (S1 Fig
and S3 Table).
For the quantitative network analyses, 219 studies were excluded due to the absence of cate-
gorical data on patient’s adherence. Another 11 trials were excluded as intervention arms were
grouped in the same category and were unable to be compared in the network (e.g. technical
vs. technical). Finally, 249 studies were included in the network meta-analyses of overall com-
posite measure for the four periods of time with studies able to be included in more than one
time period: 99 studies reporting results in the 0–3 month follow-ups, 104 in the 4–6 months,
18 in 7–9 months, 94 in�10 months. Seventy-one studies reported in more than one time
period. Six interventions, in addition to standard of care, were evaluated in all the four time
periods: attitudinal, educational, educational + attitudinal, educational + attitudinal + techni-
cal, educational + technical, and technical. The network plots of each time period with nodes
representing the interventions are presented in Fig 2. Heterogeneity between trials for the
composite measure analysis was moderate for the majority of the comparisons (81.3% I2 <
70%) (S4 Table).
From the 16 built networks, accounting for both original and sensitivity analyses, 107
nodes were split during the evaluation of inconsistency (node-splitting analyses). Overall,
results of direct and indirect evidence were consistent for all these networks (p-values > 0.050
in all cases), suggesting that conditions required for the analyses were met. Only 7 compari-
sons presented p-values close to the limit of significance (between 0.050 and 0.070). For com-
plete results of node-splitting analyses are presented in S5 Table. The effect size of all the
comparisons between interventions in each time period is presented in Table 1. The ranking
probabilities of each intervention to be the best, second best and so on is expressed as SUCRA
analysis (Fig 3 and S2 Fig).
0–3 month follow-ups
The 0–3 month network included data from 99 studies (n = 35,714 patients) and comprised 11
different nodes. Follow-up time varied from 0–3 months, with the most common period being
10–12 weeks (n = 25 studies), followed by 4–6 weeks (n = 22 studies).
4–6 month follow-ups
The 4–6 month network included data from 104 studies (n = 31,736 patients), compromising
eight arms. Follow-up time varied from 4–6 months, with the majority studies using 24–26
weeks (n = 54).
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7–9 month follow-ups
Data from 18 studies (n = 7,586 patients) were included in the 7–9 month network with stan-
dard of care and six interventions (attitudinal, educational, educational + attitudinal, educa-
tional + attitudinal + technical, educational + technical, technical). No studies reporting data
on reward components were reported in the literature for this time period. Follow-up time
varied from 7–9 months.
�10 month follow-ups
Ninety-four studies were included in the�10 month network (n = 152,372 patients) compris-
ing 11 arms. Follow-up time varied from 10–40 months, with 12 months (n = 60 studies) as
the most common.
Components of interventions
Across all time periods, multiple interventions were effective and standard of care ranked last
in all SUCRA analyses (mean SUCRA value 6%). Single component interventions were found
to be the most effective in follow-ups of 4–6 months and 7–9 months, with technical (SUCRA
Fig 2. Networks of the comparisons between interventions for each time period (0–3 months, 4–6 months, 7–9 months,�10 months) considering
the overall composite measure of adherence. Each node represents an intervention. Directly comparable interventions are linked with a line, the
number of trials for each comparison are shown in each line.
https://doi.org/10.1371/journal.pone.0213432.g002
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Table 1. Consistency analyses of multiple comparison analyses for the overall composite measure in part A: 0–3 months (top right) and 4–6 months (top left) and
part B: 7–9 months (bottom right) and�10 months (bottom left).
A
Att + Rew - - - - - - - - - - - - - - - - - - - - - -
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Effect sizes are reported as OR (with 95% CrI). Comparisons are read from left to right (row to column above, column to row below) (e.g. the effect of Edu to SOC is
0.60 in 0–3 months). An OR <1 indicates a more effective intervention. Bold data comparisons are statistically significant. Edu: educational, Att: attitudinal, Tec:
technical, Rew: rewards, SOC: standard of care.
https://doi.org/10.1371/journal.pone.0213432.t001
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value 92%) (OR 0.33, [95% CrI 0.25–0.45] vs SOC) and attitudinal (SUCRA value 84%) (OR
0.37, [95% CrI 0.17–0.84] vs. SOC) ranking first in each time period respectively. The combi-
nation of educational + technical components consistently performed well, with an average
SUCRA value around 63%, and was always more effective than educational components
alone (highest SUCRA value 53% in�10 month follow-ups). The addition of an attitudinal
component to educational + technical components past 10 months increased effectiveness
(attitudinal + educational + technical OR 0.49, [95% CrI 0.27–0.88] vs SOC; educational +
technical OR 0.56 [95% CrI 0.44–0.72] vs SOC). Rewards + technical was considered an effec-
tive intervention in the shortest time period (0–3 months; n = 1 study) and longest (�10
months; n = 1) (92% and 100% in the SUCRA analysis respectively) and presented significant
statistical differences compared to almost all interventions and standard of care (OR 0.03,
[95% CrI 0.01–0.13] vs. SOC). However, conclusions cannot be determined on this combina-
tion based on the limited amount of evidence. Other combinations including reward compo-
nents were also limited, appearing in only seven studies across all time periods with no
statistically significant comparisons.
Changes over time
To facilitate data interpretation, Fig 3 shows a summary of the changes in the position of rank
order for each intervention over time (for final rank orders see S6 Table). Considering only
the interventions reporting data on all four time periods, educational + attitudinal + technical
Fig 3. Summary of the effectiveness of the interventions over time considering the SUCRA analysis. SUCRA values can range from 0% (i.e. the
intervention always ranks last) to 100% (i.e. the intervention always ranks first).
https://doi.org/10.1371/journal.pone.0213432.g003
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presented increasing comparative effectiveness over time, with a final SUCRA value reaching
around 68% (median 46%, interquartile range [IQR] 26.0%-64.8%). Attitudinal interventions
also presented increasing values through time up until the 7–9 month follow-ups, though
dropped in effectiveness�10 months without the addition of other components. Technical
interventions presented consistent values during the time periods (around 50% probability),
except for the 4–6 month time period. In follow-ups less than 10 months, educational had a
mean 29% chance of being the best option, but this value increased to 53% past 10 months
(median 36%, IQR 30.0%-42.0%). The effectiveness of the interventions educational + attitudi-
nal and educational + technical were relatively stable during all time periods at around 40%
(IQR 39.0%-44.3%) and 63% (IQR 58.0%-64.0%), respectively. For attitudinal + rewards, atti-
tudinal + technical, attitudinal + technical + rewards, rewards and educational + attitudinal +
rewards further extrapolation was not possible due to the lack of studies reporting data for all
follow-up periods.
Sensitivity analyses
Overall, studies’ sample sizes were found to have low influence on the comparative effective-
ness of interventions. Analyses that included only studies with more than 30 patients presented
equivalent results compared to the original analyses for all four time periods. Results from sen-
sitivity analyses of articles published before 2007 or after 2007 showed that for follow-ups�10
months, differences in the position of the interventions in the rank order were observed com-
pared to the original analyses. These, however, were similar to those obtained in the original
analyses for shorter time periods. When evaluating studies published before 2007, the compar-
isons attitudinal vs. standard of care and educational + attitudinal + technical vs. standard of
care lose their statistical significance with the enlargement of the 95% CrI (OR 0.81 [95% CrI
0.38–1.74] and OR 0.89 [95% CrI 0.19–4.13], respectively). By removing these studies from the
original analyses and accounting for studies published after 2007, both interventions became
statistically superior to standard of care (0.56 [0.35–0.89] and 0.44 [0.22–0.83], respectively)
with final SUCRA values of 67% and 83%, respectively. No other significant differences were
observed (S1 File).
Discussion
By using NMAs to synthesise evidence from more than 200 studies on medication adherence,
we found that time significantly influenced some interventions, while having no influence on
others. We found a trend towards any intervention, either singly or in combination, being
more effective than standard of care, although in many cases the trend did not reach statistical
significance. This review demonstrated that multicomponent interventions including educa-
tional, attitudinal and technical aspects are more effective than single component interven-
tions. This supports other research in adherence [11], pharmacology [35] and health care
more broadly [36], and is logically reinforced by the idea that adherence is a multifaceted and
complex issue [6, 14]. While other adherence research has shown this by indirect comparison
to standard of care [20], our research has shown this by direct comparison, albeit through an
estimate.
The comparative effectiveness of complex, multicomponent interventions is not surprising.
But it raises the question of how to focus our efforts on the best combination of interventions.
We found that an adherence intervention that included a technical component, either singly
or in combination, showed benefits that were consistent across time, which builds on other
research about effectiveness [19, 21]. A technical component, such as reminders and feedback
from healthcare professionals, can be an effective and inexpensive opportunity to add to
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standard practice to improve adherence [37]. Reward components were found effective when
present in the networks, especially when combined with technical components. However, due
to the lack of studies and evidence of interventions including reward components, it is not rea-
sonable to draw conclusions or recommendations.
This review also revealed the effectiveness of interventions with an attitudinal or educa-
tional component increased with time, but declined after 10 months when used alone. How-
ever, they continued to become more effective past 10 months when in combination with
other components. A possible explanation is that while attitudinal change is important, its
effect is difficult to sustain without other elements. Similar themes have been found in other
areas of public health and psychology [36, 38]. Brehm’s motivational intensity theory states
importance and difficulty of a goal determines motivation [39]. Educational intervention com-
ponents may be necessary for patients to understand the importance of adherence while tech-
nical components can simplify the medication taking process. Thus, this allows motivation
from attitudinal components to fully develop and be sustained.
Many studies have shown that adherence declines over time [16, 17, 21]. This research
shows for the first time that the approach needed to support adherence may change over time.
Adherence to medication should not be considered a fixed concept, as it is multi-dimensional
in nature. The complexity of medication adherence behaviors are reflected in the adherence
taxonomy proposed by the ABC (Ascertaining Barriers for Compliance) Project Team [14]
and the five dimensions of medication adherence classified by WHO [40–42]. We have dem-
onstrated in this review that interventions to improve adherence can have an impact that var-
ies depending on the time at which they are used. With more than half of American adults
having at least one chronic condition [43], and with many of these conditions requiring long-
term management [44, 45], future efforts must be focused on interventions inducing adher-
ence change that is sustained for long periods.
Our strengths of this study are found in our statistical approach used. Network meta-analy-
sis creates more powerful and robust evidence compared to standard meta-analysis by using
both direct and indirect evidence [23]. All the built networks demonstrated robustness with
no significant inconsistency between direct and indirect comparisons found. This is also the
first network of its kind to evaluate adherence across all clinical conditions in addition to look-
ing at variations in effectiveness of interventions across time. By acknowledging that adher-
ence is a multi-dimensional topic affected by multiple factors including therapy-related,
condition-related, health system-related, socio-economic-related, and patient-related factors
[7], we aimed to create a broader picture of the landscape of medication adherence. This was
achieved by evaluating the patterns and changes of the effect of intervention components com-
prehensively across all clinical conditions over time, by not limiting our research to a clinical
condition, a setting or a specific intervention type. Previous research demonstrated that the
effectiveness of interventions may be related to the clinical condition [13]. Although including
different clinical conditions in the network meta-analysis may be considered as a drawback
due the potential heterogeneity induced, in our research, the four periods of evaluation contain
an almost identical mix of medical conditions. Additionally, the heterogeneity between trials
was below 70% in the vast majority of the comparisons, which is not unexpected when gather-
ing evidence about complex interventions. Moreover, we evaluated intervention effects on all
clinical conditions over time to account for the fact that determinants and issues of non-adher-
ence are often comparable across medications and disease states. [11, 12]. While our networks
were large and with many direct comparisons and a concern for heterogeneity, we can be con-
fident in our networks due to no evidence of inconsistency being found in node-splitting anal-
ysis of direct and indirect evidence. Future research efforts should continue to expand on this
landscape, including the effects of time on adherence as well as aiming to achieve the goal of
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long-term sustainability of improved adherence. Furthermore, sustainability of improved
adherence first requires implementation of adherence enhancing interventions [46], a difficult
process into the already overextended and resource-deficient practice of routine health care
[45]. While multiple intervention components may be necessary for maintenance of adher-
ence, too many components may overwhelm and produce a negative effect [47]. To support
the thinking of policy-makers and healthcare professionals, we must determine where the best
compromise in complex interventions lie for cost-effective and resource-limited approaches.
Our review has limitations. One is a lack of data across all combinations, with few trials
available for some interventions and not all possible combinations of components being evalu-
ated. Moreover, not all interventions or combinations were presented across all time periods,
preventing a full narrative of temporal trends. The methodological quality of the included trials
was mostly unclear, with a lack of complete outcome data or poor description of the study
methodology definition of the evaluated interventions, and how they were delivered. Thus,
only 53.2% of the studies could be part of the quantitative synthesis as they properly reported
categorical results on patient’s adherence.
Additionally, only studies measuring implementation adherence were included, as initial
review of the literature did not reveal enough studies reporting initiation and persistence
adherence. To assist interpretability, the adherence-enhancing interventions were grouped
into categories based on previous literature, but we acknowledge that a different approach of
categorization may alter some results. Finally, while we decided to categorize a trial arm as
standard of care if it was so determined as such by the individual study, we understand the def-
inition of standard of care may vary by country or healthcare system.
Conclusions
In conclusion, the results from this systematic review and network meta-analysis demonstrate
several interventions including educational, attitudinal, technical and multicomponent strate-
gies are effective in enhancing medication adherence. Multicomponent interventions incorpo-
rating educational, attitudinal, and technical aspects demonstrated greater sustainability of
adherence over time. Technical interventions remained consistent in effectiveness across fol-
low-up periods, while educational and attitudinal interventions were more effective with lon-
ger follow-up times, suggesting they may take more time to reach their potential in improving
medication adherence. This research can be used to guide policy-makers and healthcare pro-
fessionals in selecting effective multicomponent interventions, while future research should
evaluate cost-effectiveness of these interventions.
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